Subretinal Drusenoid Deposits Linked to High-Risk Vascular Disease in AMD

In HealthDay News
by Healthday

Presence of HRVD can be identified in model including SDD, high-density lipoprotein with accuracy of 78.5 percent

By Elana Gotkine HealthDay Reporter

FRIDAY, Nov. 18, 2022 (HealthDay News) — In patients with age-related macular degeneration (AMD), subretinal drusenoid deposits (SDD) are associated with high-risk vascular diseases (HRVD), according to a study published online Nov. 17 in BMJ Open Ophthalmology.

Gerardo Ledesma-Gil, M.D., from the Institute of Ophthalmology Fundación Conde de Valenciana in Mexico City, and colleagues conducted a cross-sectional study involving 200 individuals with AMD (aged 51 to 100 years). Individuals were classified into those with or without HRVD, defined as cardiac valve defect, myocardial defect, and stroke/transient ischemic attack. The association of coexistent HRVD with SDD status was examined.

The researchers found that the prevalence of HRVD was 41.2 and 6.8 percent in the SDD and non-SDD groups, respectively (odds ratio, 9.62). In multivariate regressions, only SDD and high-density lipoprotein (HDL) in the first two quartiles remained significant for HRVD. The presence of HRVD was identified in a multivariate regression model including SDD and an HDL in quartile 1 or 2, with accuracy of 78.5 percent.

“In summary, the strong associations found herein between HRVD and SDDs in AMD subjects warrant validation on larger and varied cohorts, which in turn might lead to inexpensive screening for HRVD in population and eye clinics,” the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Regeneron Pharmaceuticals, which funded the trial.

Abstract/Full Text

Copyright © 2022 HealthDay. All rights reserved.